Moomoo AI 已提取核心信息
Zdravka Medarova, a United States citizen, has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC) on December 31, 2023, disclosing her ownership in TransCode Therapeutics, Inc. The filing indicates that Medarova beneficially owns 112,077 shares of TransCode Therapeutics' common stock, which represents approximately 0.4% of the company's outstanding shares. This ownership includes 96,639 shares held directly and 15,438 shares issuable upon the exercise of stock options within 60 days of the reporting date. The filing also notes that these figures do not account for a 1-for-40 reverse stock split that occurred on January 16, 2024. The Schedule 13G amendment was submitted to report that Medarova now owns less than 5% of TransCode Therapeutics, as indicated by the checked box in Item 5 of the filing.
Zdravka Medarova, a United States citizen, has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC) on December 31, 2023, disclosing her ownership in TransCode Therapeutics, Inc. The filing indicates that Medarova beneficially owns 112,077 shares of TransCode Therapeutics' common stock, which represents approximately 0.4% of the company's outstanding shares. This ownership includes 96,639 shares held directly and 15,438 shares issuable upon the exercise of stock options within 60 days of the reporting date. The filing also notes that these figures do not account for a 1-for-40 reverse stock split that occurred on January 16, 2024. The Schedule 13G amendment was submitted to report that Medarova now owns less than 5% of TransCode Therapeutics, as indicated by the checked box in Item 5 of the filing.
美国公民兹德拉夫卡·梅达罗娃已于2023年12月31日向美国证券交易委员会（SEC）提交了经修订的附表13G，披露了她在TransCode Therapeutics, Inc.的所有权。该文件显示，梅达罗娃实益拥有TransCode Therapeutics普通股的112,077股，约占该公司已发行股份的0.4％。该所有权包括在报告日起60天内直接持有的96,639股股票和行使股票期权时可发行的15,438股股票。该文件还指出，这些数字并未考虑2024年1月16日发生的40比1的反向股票拆分。提交附表13G修正案的目的是报告说，梅达罗娃现在拥有TransCode Therapeutics不到5％的股份，如文件第5项中的复选框所示。
美国公民兹德拉夫卡·梅达罗娃已于2023年12月31日向美国证券交易委员会（SEC）提交了经修订的附表13G，披露了她在TransCode Therapeutics, Inc.的所有权。该文件显示，梅达罗娃实益拥有TransCode Therapeutics普通股的112,077股，约占该公司已发行股份的0.4％。该所有权包括在报告日起60天内直接持有的96,639股股票和行使股票期权时可发行的15,438股股票。该文件还指出，这些数字并未考虑2024年1月16日发生的40比1的反向股票拆分。提交附表13G修正案的目的是报告说，梅达罗娃现在拥有TransCode Therapeutics不到5％的股份，如文件第5项中的复选框所示。
有用
没用
